Samyag

Corporate Actions

Back

Ipca Laboratories Q4 PAT slumps 41% YoY to Rs 76 cr

29-May-23 15:06 Hrs IST

However, revenue from operations increased 17% to Rs 1,511.63 crore during the quarter from Rs 1,289.10 crore recorded in the corresponding quarter last year.

Total income in Q4 FY23 was at Rs 1,548.02 crore, up by 19% from Rs 1,303.64 crore posted in Q4 FY22.

Profit before tax declined 23.66% year on year to Rs 129.44 crore in the quarter ended 31 March 2023.

Total expenses spiked 25.09% to Rs 1,418.58 crore in Q4 FY23 over Q4 FY22. Employee benefits expenses stood at Rs 327.33 crore (up 9.94% YoY) while finance cost was Rs 18.45 crore (up 5x YoY).

EBITDA before forex declined 12% to Rs 206.92 crore in Q4 FY23 from Rs 236.05 crore posted in Q4 FY22. EBITDA margin reduced to 13.37% in Q4 FY23 as compared with 18.11% reported in the same period last year. The company reported forex gain of Rs 10.51 crore in Q4 FY23 as against forex loss of Rs 2.18 crore recorded in Q4 FY22.

Revenue from formulations business stood at Rs 1,040.57 crore in Q4 FY23, up by 16% YoY. During the quarter, income from domestic formulations business rose 10% at Rs 607.94 crore.

Revenue from APIs business jumped 30% YoY to Rs 346.98 crore in the quarter ended 31 March 2023.

On full year basis, the company reported 47% decline in net profit to Rs 471.32 crore despite of a 7% increase in net sales to Rs 6,244.32 crore in the financial year ended 31 March 2023 over the financial year ended 31 March 2022.

IPCA Laboratories is a pharmaceutical company with a strong thrust on exports which now account for 47% of company's income. IPCA is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.

Shares of IPCA Laboratories rose 0.92% to currently trade at Rs 689.90 on the BSE.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.